Evidence map›Paper›PMID 26021552›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2015

Circulating 25-hydroxyvitamin D3 and survival after diagnosis with kidney cancer.

David C Muller, Ghislaine Scelo, David Zaridze, Vladimir Janout, Ivana Holcatova, Marie Navratilova, Dana Mates, Øivind Midttun, Per Magne Ueland, Paul Brennan and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. 1,25DOncotarget · 2017
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

David C MullerInternational Agency for Research on Cancer (IARC), Lyon, France. JohanssonM@iarc.fr MullerD@fellows.iarc.fr.
Ghislaine SceloInternational Agency for Research on Cancer (IARC), Lyon, France.
David ZaridzeRussian N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation.
Vladimir JanoutDepartment of Preventive Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
Ivana HolcatovaCharles University in Prague, First Faculty of Medicine, Institute of Hygiene and Epidemiology, Prague, Czech Republic.
Marie NavratilovaDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Dana MatesNational Institute of Public Health, Bucharest, Romania.
Øivind MidttunBevital AS, Bergen, Norway.
Per Magne UelandDepartment of Clinical Science, University of Bergen, Bergen, Norway. Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway.
Paul BrennanInternational Agency for Research on Cancer (IARC), Lyon, France.
Mattias JohanssonInternational Agency for Research on Cancer (IARC), Lyon, France. JohanssonM@iarc.fr MullerD@fellows.iarc.fr.
University of Bergen · NO

Funding

Pooled genome-wide analysis of kidney cancer riskU01CA155309 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI SCELO, GHISLAINE · 2011 to 2014
$3.7M
NCI NIH HHS U01 CA155309NCI NIH HHS U01-CA155309World Health Organization 001
6 · The paper itself

Abstract

Prospective cohort studies have provided some evidence that circulating vitamin D is associated with risk of, and survival from, renal cell carcinoma (RCC), but it is unclear whether concentrations of vitamin D at the time of diagnosis of RCC are associated with prognosis. We conducted a case-cohort study of 630 RCC cases, including 203 deaths, from a multicenter case-control study in Eastern Europe. Vitamin D was assessed as 25-hydroxyvitamin D3 [25(OH)D3], and we used weighted Cox models to estimate hazard ratios (HR) and 95% confidence intervals (CI) by categories of season-adjusted 25(OH)D3. Higher concentrations of 25(OH)D3 were associated with lower risk of death after adjusting for stage, age, sex, and country (HR highest vs. lowest category 0.57; 95% CI, 0.34-0.97). The inverse associations of 25(OH)D3 with death were most notable among those who died from non-RCC causes and those diagnosed with early-stage disease. In summary, 25(OH)D3 concentration at diagnosis of RCC was inversely associated with all-cause mortality rates, but not specifically with RCC outcome.

Indexed as

AdultAgedAged, 80 and overCase-Control StudiesCohort StudiesFemaleHumansKidney NeoplasmsMaleMiddle AgedProspective StudiesSurvival AnalysisVitamin DVitamin D

Identifiers

PMID26021552
PMCPMC4526455
OpenAlexW2152765304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.